Merus N.V. (MRUS)
Stock Price:
$13.07 USD
0.01 (0.08%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
379.78M |
| Revenue (ttm) |
28.88M |
| Net Income (ttm) |
-69.61M |
| Shares Out |
29.06M |
| EPS (ttm) |
-2.56 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$13.07 |
| Previous Close |
$13.06 |
| Change ($) |
0.01 |
| Change (%) |
0.08% |
| Day's Open |
12.84 |
| Day's Range |
12.79 - 13.23 |
| Day's Volume |
17,681 |
| 52-Week Range |
10.18 - 20.64 |
More Stats
| Market Cap |
379.78M |
| Enterprise Value |
186.98M |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
29.06M |
| Float |
19.17M |
| EPS (basic) |
-2.64 |
| EPS (diluted) |
-2.56 |
| FCF / Share |
-2.76 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
238,176 |
| Short Ratio |
2.50 |
| Short % of Float |
1.24% |
| Beta |
0.56 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
13.15 |
| PB Ratio |
3.76 |
| Revenue |
28.88M |
| Operating Income |
-72.06M |
| Net Income |
-69.61M |
| Free Cash Flow |
-79.99M |
| Net Cash |
192.80M |
| Net Cash / Share |
6.64 |
| Gross Margin |
-86.73% |
| Operating Margin |
-249.50% |
| Profit Margin |
-241.00% |
| FCF Margin |
-276.95% |
| ROA |
-19.79% |
| ROE |
-73.72% |
| ROIC |
-194.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
6 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$19.47*
(48.97% upside)
Low
15.8
Current: $13.07
High
23.1
Target: 19.47
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 31.13 | 38.38 | 24.11 | 2.76 | 2.10 | 1.43 |
| Revenue Growth | -18.88% | 59.2% | 773.11% | 31.76% | 46.2% | - |
| Gross Profit | 31.13 | 38.38 | 24.11 | 2.76 | 2.10 | 1.43 |
| Operating Income | -58.66 | -45.74 | -38.83 | -30.67 | -25.42 | -19.16 |
| Net Income | -55.15 | -28.31 | -71.25 | -52.18 | -25.58 | -19.15 |
| Shares Outstanding | 24.22 | 22.29 | 16.09 | 14.24 | 14.24 | - |
| Earnings Per Share | -2.28 | -1.27 | -3.71 | -3.94 | -4.36 | -6.77 |
| Operating Cash Flow | -63.05 | -46.10 | -41.08 | -28.31 | -25.12 | -16.00 |
| Capital Expenditures | -2.22 | -1.83 | -0.80 | -0.55 | -0.11 | -0.17 |
| Free Cash Flow | -65.27 | -47.93 | -41.87 | -28.85 | -25.23 | -16.18 |
| Cash & Equivalents | 240 | 235 | 202 | 75.64 | 36.14 | 1.72 |
| Total Debt | 5.25 | 2.69 | - | 0.53 | 0.72 | 0.90 |
| Net Cash / Debt | 235 | 233 | 202 | 75.11 | 35.42 | 0.82 |
| Assets | 263 | 253 | 216 | 79.54 | 39.04 | 3.89 |
| Liabilities | 132 | 147 | 154 | 41.68 | 7.91 | 7.81 |
| Book Value | 131 | 106 | 62.25 | 37.86 | 31.13 | -3.91 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Merus N.V. |
| Country |
Netherlands |
| Employees |
87 |
| CEO |
Sven Ante Lundberg |
Stock Information
| Ticker Symbol |
MRUS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MRUS |
| IPO Date |
May 19, 2016 |
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II clinical trial for the treatment of gastric and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for the treatment of solid tumors with an initial focus on colorectal cancer. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore new potential combination therapies or indication. Merus has collaboration with Caris Life Sciences to detect NRG1 fusions in cancer patients. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.